About Acumen Pharmaceuticals
Acumen Pharmaceuticals is a company based in Livermore (United States) founded in 1996. Acumen Pharmaceuticals has raised $2.2 million across 4 funding rounds from investors including HHS, NeuroVentures and RA Capital. The company has 61 employees as of December 31, 2024. Acumen Pharmaceuticals offers products and services including Sabirnetug (ACU193). Acumen Pharmaceuticals operates in a competitive market with competitors including argenx, MacroGenics, Alexion, Zai Lab and Kodiak Sciences, among others.
- Headquarter Livermore, United States
- Employees 61 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Acumen Pharmaceuticals, Inc.
-
Annual Revenue
Not available
-
Net Profit
-$102.33 M (USD)-95.39as on Dec 31, 2024
-
EBITDA
-$113.84 M (USD)-86.76as on Dec 31, 2024
-
Total Equity Funding
$2.2 M (USD)
in 4 rounds
-
Latest Funding Round
$35.75 M (USD), Post-IPO
Mar 17, 2026
-
Investors
HHS
& 3 more
-
Employee Count
61
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Acumen Pharmaceuticals
Acumen Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol ABOS in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Acumen Pharmaceuticals
Acumen Pharmaceuticals offers a comprehensive portfolio of products and services, including Sabirnetug (ACU193).
Targets toxic amyloid beta oligomers to treat early Alzheimer's disease.
People of Acumen Pharmaceuticals
Unlock access to complete
Unlock access to complete
Funding Insights of Acumen Pharmaceuticals
Acumen Pharmaceuticals has successfully raised a total of $2.2M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $35.75 million completed in March 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Acumen Pharmaceuticals
Acumen Pharmaceuticals has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, NeuroVentures and RA Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Acumen Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Acumen Pharmaceuticals
Investment portfolio details for Acumen Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Acumen Pharmaceuticals
Detailed financials for Acumen Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Acumen Pharmaceuticals Comparisons
Peer comparison for Acumen Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Acumen Pharmaceuticals
Acumen Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as argenx, MacroGenics, Alexion, Zai Lab and Kodiak Sciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company focused on cancer therapeutics development.
|
|
| Locked | Locked | Locked |
Therapies for rare and devastating diseases are developed by Alexion.
|
|
| Locked | Locked | Locked |
Antibody-based therapies for cancers and inflammatory diseases are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for retinal diseases are developed by the company.
|
|
| Locked | Locked | Locked |
Antibody therapies are developed through machine learning and synthetic biology.
|
Detailed competitors of Acumen Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Acumen Pharmaceuticals
Complete news archive for Acumen Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Acumen Pharmaceuticals
Acumen Pharmaceuticals was founded in 1996 and raised its 1st funding round 10 years after it was founded.
Acumen Pharmaceuticals is headquartered in Livermore, United States. It is registered at Livermore, California, United States.
Acumen Pharmaceuticals is a funded company, having raised a total of $2.2M across 4 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Acumen Pharmaceuticals is 61.
Acumen Pharmaceuticals was founded in 1996 and is headquartered in Livermore, United States. Monoclonal antibody therapeutics for Alzheimers disease are developed through a proprietary platform focused on fully humanized antibodies selective for abeta oligomers. These antibodies are also intended for use as diagnostic agents to measure abeta oligomer levels in cerebrospinal fluid, supporting efforts in the biotechnology sector.
Acumen Pharmaceuticals's top competitors include argenx, Zai Lab and Kodiak Sciences.
Acumen Pharmaceuticals offers Sabirnetug (ACU193).
Yes, Acumen Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol ABOS.
Acumen Pharmaceuticals has 4 investors. Key investors include HHS, NeuroVentures, RA Capital, and Sands Capital.
The ticker symbol of Acumen Pharmaceuticals is ABOS on NASDAQ.